Discovery Laboratories, Inc. (NASDAQ:DSCO)

CAPS Rating: 4 out of 5

A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.


Player Avatar grahamfordummies (65.81) Submitted: 12/30/2013 3:54:45 PM : Outperform Start Price: $2.26 DSCO Score: -45.21

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.

Featured Broker Partners